Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00286936
(Slow inclusion resulting in premature termination due to logistics)
To examine the influence of regular hypnotic therapy on the incidence of delirium after hip fracture surgery
Condition or disease
Delirium is prevalent after hip fracture surgery. Delirium has been linked to postoperative sleep disturbances. Zolpidem is a non-benzodiazepine hypnotic that preserves REM sleep. The present study investigates the incidence of delirium in hip fracture patients randomized to Zolpidem treatment 5 mg vs placebo in the perioperative phase.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
70 Years and older (Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary hip fracture, no substance abuse, no regular opioid, corticosteroid or benzodiazepine therapy, hepatic insufficiency, myastenia gravis, allergies to drug components
Keywords provided by Hvidovre University Hospital:
Additional relevant MeSH terms:
Wounds and Injuries
Nervous System Diseases
Signs and Symptoms
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
Molecular Mechanisms of Pharmacological Action